JP2021524249A5 - - Google Patents

Info

Publication number
JP2021524249A5
JP2021524249A5 JP2020565282A JP2020565282A JP2021524249A5 JP 2021524249 A5 JP2021524249 A5 JP 2021524249A5 JP 2020565282 A JP2020565282 A JP 2020565282A JP 2020565282 A JP2020565282 A JP 2020565282A JP 2021524249 A5 JP2021524249 A5 JP 2021524249A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
seq
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020565282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524249A (ja
JP7530299B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/054188 external-priority patent/WO2019224717A2/en
Publication of JP2021524249A publication Critical patent/JP2021524249A/ja
Publication of JP2021524249A5 publication Critical patent/JP2021524249A5/ja
Priority to JP2024087232A priority Critical patent/JP2024116190A/ja
Application granted granted Critical
Publication of JP7530299B2 publication Critical patent/JP7530299B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565282A 2018-05-24 2019-05-21 抗ｃｄ３抗体及びその使用 Active JP7530299B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024087232A JP2024116190A (ja) 2018-05-24 2024-05-29 抗ｃｄ３抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862676081P 2018-05-24 2018-05-24
US62/676,081 2018-05-24
PCT/IB2019/054188 WO2019224717A2 (en) 2018-05-24 2019-05-21 Anti-cd3 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024087232A Division JP2024116190A (ja) 2018-05-24 2024-05-29 抗ｃｄ３抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2021524249A JP2021524249A (ja) 2021-09-13
JP2021524249A5 true JP2021524249A5 (enExample) 2022-05-25
JP7530299B2 JP7530299B2 (ja) 2024-08-07

Family

ID=67211773

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020565282A Active JP7530299B2 (ja) 2018-05-24 2019-05-21 抗ｃｄ３抗体及びその使用
JP2024087232A Withdrawn JP2024116190A (ja) 2018-05-24 2024-05-29 抗ｃｄ３抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024087232A Withdrawn JP2024116190A (ja) 2018-05-24 2024-05-29 抗ｃｄ３抗体及びその使用

Country Status (38)

Country Link
US (2) US11603405B2 (enExample)
EP (2) EP3802608B1 (enExample)
JP (2) JP7530299B2 (enExample)
KR (1) KR20210012007A (enExample)
CN (2) CN120058941A (enExample)
AR (1) AR115422A1 (enExample)
AU (2) AU2019274656B2 (enExample)
BR (1) BR112020023508A2 (enExample)
CA (1) CA3101271A1 (enExample)
CL (1) CL2020003033A1 (enExample)
CO (1) CO2020014506A2 (enExample)
CR (1) CR20200568A (enExample)
DK (1) DK3802608T3 (enExample)
EA (1) EA202092847A1 (enExample)
EC (1) ECSP20075215A (enExample)
ES (1) ES3032856T3 (enExample)
FI (1) FI3802608T3 (enExample)
HR (1) HRP20250621T1 (enExample)
HU (1) HUE072251T2 (enExample)
IL (1) IL278846A (enExample)
JO (1) JOP20200302A1 (enExample)
LT (1) LT3802608T (enExample)
MA (1) MA52773B1 (enExample)
MX (1) MX420253B (enExample)
NI (1) NI202000089A (enExample)
PE (1) PE20210132A1 (enExample)
PH (1) PH12020551920A1 (enExample)
PL (1) PL3802608T3 (enExample)
PT (1) PT3802608T (enExample)
RS (1) RS66901B1 (enExample)
SA (1) SA520420631B1 (enExample)
SG (1) SG11202011270QA (enExample)
SI (1) SI3802608T1 (enExample)
SM (1) SMT202500221T1 (enExample)
UA (1) UA129050C2 (enExample)
UY (1) UY38245A (enExample)
WO (1) WO2019224717A2 (enExample)
ZA (1) ZA202007936B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
EA202092849A1 (ru) 2018-05-24 2021-03-16 Янссен Байотек, Инк. Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
MX2020012598A (es) 2018-05-24 2021-05-27 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos.
LT4324851T (lt) 2018-07-19 2025-10-10 Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
JP7686571B2 (ja) 2019-05-08 2025-06-02 ヤンセン バイオテツク，インコーポレーテツド Ｔ細胞媒介性免疫を調節するための材料及び方法
CR20220025A (es) 2019-07-26 2022-05-04 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos
PH12022551470A1 (en) * 2019-12-18 2023-05-03 Janssen Biotech Inc Materials and methods for in vivo biological targeting
CA3173268A1 (en) * 2020-02-27 2021-09-02 Janssen Biotech, Inc. Materials and methods for modulating an immune response
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
KR20230008775A (ko) 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
PE20230389A1 (es) 2020-05-27 2023-03-06 Janssen Biotech Inc Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
JP7862361B2 (ja) 2020-07-29 2026-05-19 ヤンセン バイオテツク，インコーポレーテツド Ｈｌａ－ｇ抗原結合ドメインを含むタンパク質及びそれらの使用
JP2023539525A (ja) * 2020-09-02 2023-09-14 ジェンマブ エー／エス 抗体療法
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
WO2022068809A1 (zh) * 2020-09-29 2022-04-07 信达生物制药(苏州)有限公司 抗cd3抗体以及其用途
US20240025992A1 (en) 2020-10-22 2024-01-25 Janssen Biotech, Inc. Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
WO2022175255A2 (en) * 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
MX2023013714A (es) 2021-05-21 2024-01-16 Leo Pharma As Anticuerpos anti-proteina accesoria del receptor de interleucina 1 (il-1).
WO2023026235A1 (en) * 2021-08-27 2023-03-02 Janssen Biotech, Inc. Anti-psma antibodies and uses thereof
US12600764B2 (en) 2021-08-27 2026-04-14 International Business Machines Corporation Antigen-binding proteins targeting coronavirus (COV) variants
CN118974087A (zh) * 2022-03-09 2024-11-15 德琪(杭州)生物有限公司 新颖的抗cd3抗体以及其用途
WO2023178645A1 (zh) * 2022-03-25 2023-09-28 嘉和生物药业有限公司 靶向cd3的抗体及其应用
US12054552B2 (en) * 2022-09-21 2024-08-06 Sanofi Biotechnology Humanized anti-IL-1R3 antibody and methods of use
EP4598958A1 (en) 2022-10-05 2025-08-13 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024089551A1 (en) 2022-10-25 2024-05-02 Janssen Biotech, Inc. Msln and cd3 binding agents and methods of use thereof
WO2024126833A1 (en) * 2022-12-16 2024-06-20 Ichnos Sciences SA Cd47-il1rap bispecific antibodies
WO2025134050A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
WO2025134049A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
TW202602940A (zh) 2024-04-09 2026-01-16 美商安進公司 激動性抗ｉｌ－２ｒｂｇ重鏈抗體
WO2025230233A1 (ko) * 2024-05-03 2025-11-06 국민대학교산학협력단 인간 cd3에 특이적인 항체 및 이의 용도
WO2025259563A2 (en) * 2024-06-10 2025-12-18 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026078647A1 (en) 2024-10-11 2026-04-16 Janssen Biotech, Inc. Combination of trispecific antibody targeting bcma, gprc5d and cd3, and pomalidomide for the treatment of multiple myeloma
US20260102490A1 (en) 2024-10-11 2026-04-16 Janssen Biotech, Inc. Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
ES2243007T3 (es) 1997-09-16 2005-11-16 Egea Biosciences Llc Sintesis quimica completa y sintesis de genes de genomas.
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
DK1999154T3 (da) 2006-03-24 2012-12-03 Merck Patent Gmbh Fremstillede heterodimere proteindomæner
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CN101952312A (zh) 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
WO2012162067A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014093908A2 (en) 2012-12-14 2014-06-19 Omt, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
KR102813816B1 (ko) * 2013-07-05 2025-05-29 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
HUE050159T2 (hu) * 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
CN106459201A (zh) * 2014-05-28 2017-02-22 豪夫迈·罗氏有限公司 结合人和食蟹猴CD3ε的抗体
EP2982693A1 (en) 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
AR103488A1 (es) * 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
BR112018008908A2 (pt) 2015-11-02 2018-11-27 Janssen Pharmaceutica Nv anticorpos anti-il1rap, moléculas de ligação ao antígeno biespecíficas que se ligam il1rap e cd3, e seus usos
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
MX2020012598A (es) 2018-05-24 2021-05-27 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos.
EA202092849A1 (ru) 2018-05-24 2021-03-16 Янссен Байотек, Инк. Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها

Similar Documents

Publication Publication Date Title
FI3802608T3 (fi) Cd3-vasta-aineita ja niiden käyttötapoja
JP2023113893A5 (enExample)
JP2020103301A5 (enExample)
JP2020520370A5 (enExample)
JP2021531764A5 (enExample)
JP2021531005A5 (enExample)
JP2022509065A5 (enExample)
JP2020501531A5 (enExample)
JP2022510964A5 (enExample)
JP2023543152A5 (enExample)
JP2020528750A5 (enExample)
JP2018534933A5 (enExample)
AU2018268304A1 (en) Anti-SIRPα antibodies
FI3618863T3 (fi) Anti-TIGIT-vasta-aineita ja menetelmiä niiden käyttämiseksi
RU2010129045A (ru) Связывающие молекулы к рецептору ох40 человека
JP2022525071A5 (enExample)
JP2022545741A5 (enExample)
JP2023518153A5 (enExample)
IL272770B1 (en) CD40 agonist antibodies
JP2021524255A5 (enExample)
RU2017114968A (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
JP2021520201A5 (enExample)
JP2024532886A5 (enExample)
JP2024538669A5 (enExample)
JP2024540148A5 (enExample)